Latest news
Why Halozyme Therapeutics Is Surging 14.9%: Wells Fargo Maintains Equal-Weight - AlphaStreetAlphaStreet · Fri, 07 Aug 2026 14:45:00 GMTDoes Xencor’s Mixed 2026 Loss Trend Reshape the Investment Narrative Around XNCR’s R&D Priorities? - simplywall.stsimplywall.st · Thu, 06 Aug 2026 16:39:58 GMTICON (ICLR) Earnings Reset Keeps Valuation In Focus As Investors Weigh The Rebound - simplywall.stsimplywall.st · Wed, 05 Aug 2026 05:58:00 GMTEdgewise Therapeutics gains as investors weigh cash-rich reset and cardiovascular pipeline progress - Quiver QuantitativeQuiver Quantitative · Tue, 04 Aug 2026 21:26:00 GMTWill Pacira’s (PCRX) U.S. Manufacturing Shift for PCRX-201 Redefine Its Post-EXPAREL Narrative? - simplywall.stsimplywall.st · Sun, 02 Aug 2026 02:16:19 GMTALX Oncology Holdings (ALXO) Slips Marginally as Investors Weigh Clinical Pipeline Against Cash Position - Market Cap Weight - dars.gov.etdars.gov.et · Sat, 01 Aug 2026 02:37:28 GMTGlaukos Rises as Investors Weigh Clinical Progress Ahead of Earnings - Quiver QuantitativeQuiver Quantitative · Wed, 29 Jul 2026 16:26:00 GMTCapricor Faces Make-Or-Break FDA Panel For Duchenne Cell Therapy — Experts And Investors Weigh In - StocktwitsStocktwits · Wed, 29 Jul 2026 07:00:00 GMT